Cargando…

Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy

PURPOSE: Owing to the important mechanistic implications in the pathogenesis of cardiac hypertrophy and heart failure, inflammation has been proposed as a druggable target for the treatment of cardiac hypertrophy and heart failure. Ginseng is a widely used medicinal herb for the treatment of cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shihua, Cui, Yimeng, Xiong, Minqi, Li, Mei, Wang, Peiwei, Cui, Jingang, Du, Xiaoye, Chen, Yu, Zhang, Teng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108398/
https://www.ncbi.nlm.nih.gov/pubmed/33981156
http://dx.doi.org/10.2147/JIR.S310633
_version_ 1783690122666967040
author Wang, Shihua
Cui, Yimeng
Xiong, Minqi
Li, Mei
Wang, Peiwei
Cui, Jingang
Du, Xiaoye
Chen, Yu
Zhang, Teng
author_facet Wang, Shihua
Cui, Yimeng
Xiong, Minqi
Li, Mei
Wang, Peiwei
Cui, Jingang
Du, Xiaoye
Chen, Yu
Zhang, Teng
author_sort Wang, Shihua
collection PubMed
description PURPOSE: Owing to the important mechanistic implications in the pathogenesis of cardiac hypertrophy and heart failure, inflammation has been proposed as a druggable target for the treatment of cardiac hypertrophy and heart failure. Ginseng is a widely used medicinal herb for the treatment of cardiovascular disorders. As one of the major chemical components of ginseng, ginsenoside Rb1 (Rb1) contributes to the cardiovascular effects of ginseng. Meanwhile, anti-inflammatory activity of Rb1 has also been documented. The current work aims to further delineate the pharmacological implications of Rb1 in the treatment of cardiac hypertrophy. METHODS: Angiotensin II (Ang II) infusion mouse model was adopted to investigate the effects of Rb1 on cardiac hypertrophic remodeling and associated inflammation in vivo. Furthermore, the mechanisms of actions of Rb1 in modulating the hypertrophic and inflammatory responses were investigated in cardiomyocytes and macrophages, respectively. RESULTS: Rb1 mitigates Ang II–induced cardiac hypertrophy, cardiac inflammation and systemic inflammation in vivo. In cardiomyocytes, Rb1 directly counteracts the pro-hypertrophic effects of Ang II and phenylephrine and maintains the mitochondrial function. In lipopolysaccharide (LPS)-stimulated macrophages, Rb1 decreases the phosphorylation of mitogen-activated protein kinases (MAPKs) and mitogen-activated protein kinase kinase 1/2 (MEK1/2) and reduces the production of inflammation mediators such as interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF). Rb1 also suppresses the expression of pro-hypertrophic microRNA-155 (miR-155) in LPS- or Ang II-stimulated macrophages. Furthermore, in activated macrophages, miR-155 is in part accountable for the suppressive effect of Rb1 on the production of IL-6, an inflammation mediator with pro-hypertrophic functions in the heart. CONCLUSION: The work here provides novel experimental evidence supporting the notion that Rb1 protects against cardiac hypertrophy in part through suppressing the inflammatory mechanisms that promotes the pathological remodeling of the heart.
format Online
Article
Text
id pubmed-8108398
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81083982021-05-11 Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy Wang, Shihua Cui, Yimeng Xiong, Minqi Li, Mei Wang, Peiwei Cui, Jingang Du, Xiaoye Chen, Yu Zhang, Teng J Inflamm Res Original Research PURPOSE: Owing to the important mechanistic implications in the pathogenesis of cardiac hypertrophy and heart failure, inflammation has been proposed as a druggable target for the treatment of cardiac hypertrophy and heart failure. Ginseng is a widely used medicinal herb for the treatment of cardiovascular disorders. As one of the major chemical components of ginseng, ginsenoside Rb1 (Rb1) contributes to the cardiovascular effects of ginseng. Meanwhile, anti-inflammatory activity of Rb1 has also been documented. The current work aims to further delineate the pharmacological implications of Rb1 in the treatment of cardiac hypertrophy. METHODS: Angiotensin II (Ang II) infusion mouse model was adopted to investigate the effects of Rb1 on cardiac hypertrophic remodeling and associated inflammation in vivo. Furthermore, the mechanisms of actions of Rb1 in modulating the hypertrophic and inflammatory responses were investigated in cardiomyocytes and macrophages, respectively. RESULTS: Rb1 mitigates Ang II–induced cardiac hypertrophy, cardiac inflammation and systemic inflammation in vivo. In cardiomyocytes, Rb1 directly counteracts the pro-hypertrophic effects of Ang II and phenylephrine and maintains the mitochondrial function. In lipopolysaccharide (LPS)-stimulated macrophages, Rb1 decreases the phosphorylation of mitogen-activated protein kinases (MAPKs) and mitogen-activated protein kinase kinase 1/2 (MEK1/2) and reduces the production of inflammation mediators such as interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF). Rb1 also suppresses the expression of pro-hypertrophic microRNA-155 (miR-155) in LPS- or Ang II-stimulated macrophages. Furthermore, in activated macrophages, miR-155 is in part accountable for the suppressive effect of Rb1 on the production of IL-6, an inflammation mediator with pro-hypertrophic functions in the heart. CONCLUSION: The work here provides novel experimental evidence supporting the notion that Rb1 protects against cardiac hypertrophy in part through suppressing the inflammatory mechanisms that promotes the pathological remodeling of the heart. Dove 2021-05-05 /pmc/articles/PMC8108398/ /pubmed/33981156 http://dx.doi.org/10.2147/JIR.S310633 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Shihua
Cui, Yimeng
Xiong, Minqi
Li, Mei
Wang, Peiwei
Cui, Jingang
Du, Xiaoye
Chen, Yu
Zhang, Teng
Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
title Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
title_full Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
title_fullStr Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
title_full_unstemmed Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
title_short Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
title_sort dual activity of ginsenoside rb1 in hypertrophic cardiomyocytes and activated macrophages: implications for the therapeutic intervention of cardiac hypertrophy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108398/
https://www.ncbi.nlm.nih.gov/pubmed/33981156
http://dx.doi.org/10.2147/JIR.S310633
work_keys_str_mv AT wangshihua dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT cuiyimeng dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT xiongminqi dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT limei dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT wangpeiwei dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT cuijingang dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT duxiaoye dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT chenyu dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy
AT zhangteng dualactivityofginsenosiderb1inhypertrophiccardiomyocytesandactivatedmacrophagesimplicationsforthetherapeuticinterventionofcardiachypertrophy